Direct oral anticoagulants (DOACs) are indicated for stroke prevention in patients with
nonvalvular atrial fibrillation (NVAF), which, according to the American College of …

Direct oral anticoagulants (DOACs) are indicated by the European Medicines Agency and
US Food and Drug Administration for stroke prevention in patients with nonvalvular atrial …

Background Current guidelines recommend direct-acting oral anticoagulants (DOACs) over
warfarin in patients with atrial fibrillation (AF) and valvular heart disease (VHD) without a …

The non-vitamin K antagonist oral anticoagulants (NOACs) dabigatran, rivaroxaban,
apixaban, and edoxaban have transformed the management of atrial fibrillation (AF), but are …

Direct oral anticoagulants (DOACs) represent the cornerstone therapy for cardioembolic
events prevention in patients with nonvalvular atrial fibrillation (NVAF). In practice, the …

Abstract Background Direct oral anticoagulants (DOACs) have been developed for stroke
prevention in patients with non-valvular atrial fibrillation (NVAF). We conducted a …

Atrial fibrillation (AF) is the most common sustained cardiac dysrhythmia, and is associated
with an increased risk of death, stroke, and other thromboembolic events. Valvular heart …

Background: Direct oral anticoagulants (DOACS) are approved for use in non-valvular atrial
fibrillation (AF). This systematic review and meta-analysis aimed to evaluate the efficacy and …

Purpose: There is uncertainty as to which anticoagulant should be used in non-valvular
atrial fibrillation (AF) with valvular heart disease. This systematic review and meta-analysis …

Valvular heart disease is frequently complicated by atrial fibrillation, which is associated with
an increased risk of mortality. In the presence of a surgical or transcatheter bioprosthetic …